Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q149M9
UPID:
NWD1_HUMAN
Alternative names:
-
Alternative UPACC:
Q149M9; C9J021; Q68CT3
Background:
NACHT domain- and WD repeat-containing protein 1, identified by the accession number Q149M9, is implicated in the regulation of androgen receptor (AR) protein levels. This protein's structure, characterized by the presence of a NACHT domain and WD repeats, suggests a role in protein-protein interactions, potentially influencing AR stability and function.
Therapeutic significance:
Understanding the role of NACHT domain- and WD repeat-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in regulating androgen receptor levels highlights its potential as a target in diseases where AR plays a pivotal role.